RUSFERTIDE ACETATE - Generic Drug Details

« Back to Dashboard

What are the generic sources for rusfertide acetate and what is the scope of freedom to operate?

Rusfertide acetate is the generic ingredient in one branded drug marketed by Takeda Pharms Am and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RUSFERTIDE ACETATE

Constraining patent/regulatory exclusivity:

10,030,061

Dosage:

POWDER;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for RUSFERTIDE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Am	MIMRYLO	rusfertide acetate	POWDER;SUBCUTANEOUS	220605-005	Aug 28, 2026		RX	Yes	Yes	10,442,846		Y	Y
Takeda Pharms Am	MIMRYLO	rusfertide acetate	POWDER;SUBCUTANEOUS	220605-003	Aug 28, 2026		RX	Yes	Yes
Takeda Pharms Am	MIMRYLO	rusfertide acetate	POWDER;SUBCUTANEOUS	220605-002	Aug 28, 2026		RX	Yes	Yes
Takeda Pharms Am	MIMRYLO	rusfertide acetate	POWDER;SUBCUTANEOUS	220605-001	Aug 28, 2026		RX	Yes	Yes	12,269,856

International Patents for RUSFERTIDE ACETATE

Country	Patent Number	Title	Estimated Expiration
Australia	2014232954
Australia	2018260800
Canada	2906830
China	105451755

Rusfertide Acetate Market Dynamics and Financial Trajectory

Last updated: October 5, 2026

Rusfertide acetate is an investigational hepcidin mimetic being developed by Protagonist Therapeutics and Takeda for polycythemia vera and other hematologic disorders. It has no FDA approval, commercial sales, Orange Book listing, or established product revenue. Its financial value depends on the Phase 3 VERIFY trial, regulatory approval, differentiation from phlebotomy and existing cytoreductive therapies, and the economics of its Takeda collaboration.

What is rusfertide acetate and which patients could it treat?

Rusfertide, formerly PTG-300, is a synthetic peptide that mimics hepcidin, the hormone that regulates systemic iron availability. By reducing iron absorption and iron release into circulation, rusfertide is intended to control erythropoiesis and reduce the need for therapeutic phlebotomy in polycythemia vera.

The primary commercial opportunity is polycythemia vera, a chronic myeloproliferative neoplasm characterized by excessive red-cell production and elevated thrombotic risk. The drug is being developed for patients who require repeated phlebotomies despite background treatment.

Attribute	Rusfertide
Active drug	Rusfertide
Former development code	PTG-300
Developer	Protagonist Therapeutics
Commercial partner	Takeda
Drug class	Hepcidin mimetic peptide
Administration	Subcutaneous injection
Lead indication	Polycythemia vera
Development stage	Phase 3
FDA approval	None
Commercial revenue	None
Orange Book status	No listing
Biosimilar relevance	Not applicable

Rusfertide has also been studied in hereditary hemochromatosis and beta-thalassemia, but polycythemia vera is the principal value driver.

When could rusfertide lose exclusivity?

Rusfertide has no approved-product exclusivity date because the FDA has not approved it. No commercial launch date, New Chemical Entity exclusivity period, or generic-entry date has been established.

If approved, exclusivity would depend on the final regulatory pathway and the patents granted to Protagonist, Takeda, or related entities. Potential protections could include:

• Composition-of-matter claims covering the peptide;
• Pharmaceutical-composition claims;
• Formulation and stability claims;
• Subcutaneous delivery claims;
• Manufacturing-process claims;
• Method-of-use claims for reducing phlebotomy requirements in polycythemia vera;
• Method-of-use claims for iron-overload disorders.

The duration of protection cannot be inferred reliably from the development code or collaboration announcements. A precise patent-expiration analysis requires claim-by-claim review of issued patents, patent-term adjustments, terminal disclaimers, and any future Orange Book listings.

What is the FDA regulatory status of rusfertide?

Rusfertide is not FDA-approved and cannot currently be marketed in the United States. The principal registrational program is the Phase 3 VERIFY study in polycythemia vera. Earlier studies included REVIVE, a Phase 2 trial that evaluated rusfertide in patients with polycythemia vera who required phlebotomy or had poor control of hematocrit.

The regulatory case depends on whether rusfertide demonstrates:

1. Sustained hematocrit control;
2. A meaningful reduction in phlebotomy burden;
3. Acceptable thrombotic and injection-site safety;
4. Benefit across relevant background therapies;
5. Durable treatment effect in a chronic disease setting.

The likely regulatory positioning is as an adjunct or alternative to current cytoreductive treatment rather than as a direct replacement for every existing therapy. FDA approval would probably require a defined population with inadequate hematocrit control or excessive phlebotomy needs.

How large is the commercial market for rusfertide?

The addressable market is concentrated but clinically significant. Polycythemia vera is a chronic condition with a long treatment duration, which supports recurring revenue if rusfertide demonstrates durable benefit and gains reimbursement.

Current management includes:

• Therapeutic phlebotomy;
• Low-dose aspirin;
• Hydroxyurea;
• Ruxolitinib;
• Ropeginterferon alfa-2b;
• Other cytoreductive approaches in selected patients.

Rusfertide’s commercial differentiation is the potential to control iron-restricted erythropoiesis while reducing repeated phlebotomy. That positioning could support use in patients with persistent hematocrit instability, iron deficiency caused by phlebotomy, or inadequate response to standard cytoreduction.

The product’s market ceiling will depend on four factors:

Market factor	Commercial effect
Reduction in phlebotomy frequency	Supports medical-need and health-economic arguments
Injection burden	May constrain uptake relative to oral drugs
Use with existing therapy	Expands the market but may increase payer scrutiny
Long-term safety	Determines use in chronic maintenance treatment

No reliable public product-sales forecast exists because rusfertide has not reached commercialization. Any valuation based on peak sales remains scenario-dependent.

What is the financial trajectory for rusfertide?

Rusfertide does not yet generate product revenue. Its financial trajectory is milestone-driven for Protagonist and pipeline-driven for Takeda.

The Takeda relationship gives rusfertide access to a large pharmaceutical commercialization platform and shifts substantial late-stage development and launch responsibilities away from Protagonist. The collaboration also creates potential milestone and royalty economics for Protagonist, although the companies do not report rusfertide sales because there are no commercial sales.

Protagonist Therapeutics

For Protagonist, rusfertide has strategic value beyond direct product revenue:

• Potential development, regulatory, and commercial milestones;
• Tiered royalties or other commercial economics if approved;
• Validation of the company’s peptide-discovery platform;
• Reduced need to fund a global commercial infrastructure independently;
• Concentration risk if the VERIFY program fails or is delayed.

The asset can create a sharp change in Protagonist’s financial profile if it reaches approval. Before approval, the program primarily affects cash runway, research and development expense, milestone expectations, and investor valuation.

Takeda

For Takeda, rusfertide is a specialty hematology opportunity that could complement its oncology and rare-disease portfolio. Takeda bears the opportunity cost of late-stage investment and commercial preparation but gains control of a potentially differentiated treatment for a chronic hematologic disease.

Takeda does not publicly disclose a standalone rusfertide revenue forecast or product-level operating margin. The commercial decision will depend on the size of the treatable population, reimbursement, injection pricing, and whether rusfertide is used before or after established cytoreductive therapies.

What clinical results drive the market outlook?

The strongest commercial signal would be a statistically robust and clinically meaningful reduction in phlebotomy requirements accompanied by durable hematocrit control.

Investors and potential commercial partners will focus on:

• The proportion of patients maintaining hematocrit below the accepted treatment threshold without phlebotomy;
• Time to first phlebotomy;
• Annualized phlebotomy reduction;
• Symptom improvement;
• Iron-status normalization;
• Thrombotic events;
• Treatment discontinuations;
• Injection-site reactions;
• Results in patients receiving hydroxyurea, ruxolitinib, or interferon.

The principal clinical risk is that hematocrit control may improve without producing a benefit that payers or physicians consider large enough to justify chronic injectable treatment. Another risk is that rusfertide may be adopted mainly as add-on therapy, increasing efficacy but also increasing total treatment cost.

What formulations and manufacturing issues affect rusfertide?

Rusfertide is a peptide administered by subcutaneous injection. Its commercial formulation must support:

• Chemical and physical stability;
• Consistent peptide purity;
• Scalable synthesis;
• Reproducible dose delivery;
• Acceptable injection volume;
• Suitable storage and distribution conditions.

Peptide manufacturing can create barriers to rapid generic competition, particularly when the product requires complex analytical characterization, specialized synthesis, or proprietary formulation controls. These barriers do not replace patent protection, but they can delay competitive entry after patent expiry.

Potential formulation and manufacturing patents could protect specific peptide sequences, salts, excipients, concentration ranges, container systems, or production processes. Public commercial materials do not establish a complete list of issued claims or their expiration dates.

What is the Orange Book status of rusfertide?

Rusfertide has no Orange Book listing because it is not an FDA-approved drug. There are no listed patents, pediatric exclusivity entries, approved labeling restrictions, or Paragraph IV disputes associated with a marketed rusfertide product.

What generic entry risks exist?

Generic entry is not an immediate risk. Before approval, the relevant risks are clinical failure, regulatory delay, manufacturing setbacks, and commercial underperformance.

After approval, the competitive pathway may involve an Abbreviated New Drug Application, a 505(b)(2) application, or a more complex peptide-development pathway, depending on FDA classification and the reference product’s final characterization. A biosimilar pathway would not normally apply because rusfertide is a synthetic peptide rather than a biologic approved under the Public Health Service Act.

Which companies are challenging rusfertide?

No company is publicly identified as having filed a Paragraph IV challenge to rusfertide. The principal competitive threats are existing therapies rather than generic challengers.

Competitor	Product type	Competitive relevance
Hydroxyurea	Oral cytoreductive drug	Established, low-cost standard
Ruxolitinib	JAK inhibitor	Used in selected inadequately controlled patients
Ropeginterferon alfa-2b	Long-acting interferon	Disease-control and treatment-duration alternative
Phlebotomy	Procedure	Low drug cost but recurring burden
Rusfertide	Hepcidin mimetic peptide	Potential reduction in phlebotomy dependence

Rusfertide may compete with these products as an add-on rather than as a single-agent replacement. That distinction affects pricing, payer coverage, and sales-force requirements.

What patent litigation and settlement agreements affect rusfertide?

No public rusfertide patent litigation, Paragraph IV litigation, or generic settlement agreement has been established in the cited development record. Because the product is pre-approval, litigation exposure is more likely to arise from patent ownership, inventorship, licensing scope, or future competing peptide programs than from an Abbreviated New Drug Application challenge.

The Takeda-Protagonist collaboration is the central commercial agreement affecting rights and economics. It gives Takeda a major role in development and commercialization while preserving potential economic participation for Protagonist. The precise allocation of geographic rights, milestones, royalties, and termination rights should be reviewed against the operative agreement and subsequent amendments rather than inferred from press summaries.

How strong is the rusfertide competitive position?

Rusfertide has a differentiated biological mechanism and a clear treatment burden to address. Its strongest commercial attributes are:

• Direct relevance to phlebotomy-dependent polycythemia vera;
• Potential reduction in repeated procedures;
• Potential improvement in iron deficiency caused by phlebotomy;
• Strategic support from Takeda;
• A specialty-market profile compatible with focused commercialization.

Its main weaknesses are:

• No approval or sales history;
• Subcutaneous administration;
• Need for chronic treatment;
• Dependence on Phase 3 confirmation;
• Potential use alongside, rather than instead of, existing therapies;
• Unresolved price and reimbursement positioning;
• Limited publicly disclosed product-level financial data.

What are the likely launch scenarios?

Positive scenario

VERIFY confirms durable hematocrit control and materially reduces phlebotomy. FDA approval follows, Takeda positions rusfertide for inadequately controlled or phlebotomy-dependent patients, and adoption expands into earlier lines of treatment.

Intermediate scenario

Approval is limited to a narrower population. Rusfertide is used mainly as add-on therapy in patients who fail hydroxyurea, interferon, or ruxolitinib. Revenue grows, but payer controls and injection burden limit penetration.

Negative scenario

The Phase 3 program fails to demonstrate a sufficient clinical or safety benefit, or the FDA requires additional studies. The asset produces no product revenue, while Protagonist loses milestone visibility and Takeda may reduce investment.

Key Takeaways

• Rusfertide acetate is an investigational hepcidin mimetic for polycythemia vera, not an approved product.
• It has no commercial revenue, Orange Book listing, FDA exclusivity period, or generic challenge.
• The Phase 3 VERIFY study is the principal value catalyst.
• The commercial thesis depends on reducing phlebotomy while maintaining durable hematocrit control.
• Takeda provides global development and commercialization capacity, while Protagonist retains milestone and royalty exposure.
• The main competitive threats are hydroxyurea, ruxolitinib, ropeginterferon alfa-2b, and phlebotomy.
• Patent strength and expiration cannot be determined from development-stage disclosures alone.
• The largest financial risk is clinical failure or approval limited to a narrow, heavily pretreated population.

FAQs

Is rusfertide acetate approved by the FDA?

No. Rusfertide remains investigational and has no approved U.S. label.

Does rusfertide have an Orange Book patent listing?

No. It is not an FDA-approved product and therefore has no current Orange Book listing.

Who owns rusfertide?

Protagonist Therapeutics discovered and developed rusfertide, while Takeda is the major development and commercialization partner under a collaboration agreement.

Is rusfertide a biologic or a generic drug?

Rusfertide is a synthetic peptide. It is not a biosimilar, and a future competitive application would depend on FDA classification and the approved product’s regulatory pathway.

What would make rusfertide commercially successful?

The key requirement is durable hematocrit control with a clinically meaningful reduction in phlebotomy and acceptable long-term safety at a price supported by payers.

References

1. ClinicalTrials.gov. (n.d.). Study of rusfertide in participants with polycythemia vera: VERIFY. U.S. National Library of Medicine.

2. ClinicalTrials.gov. (n.d.). A study of PTG-300 in patients with polycythemia vera: REVIVE. U.S. National Library of Medicine.

3. Protagonist Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

4. Takeda Pharmaceutical Company Limited. (2019). Takeda and Protagonist Therapeutics enter into license and collaboration agreement for PTG-300. Takeda investor and corporate communications.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.